New drug combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that cannot be removed with surgery and has spread to other parts of the body.
- Your cancer has a normal (wild-type) RAS and BRAF gene, meaning no mutations in these genes.
- You have already tried at least three chemotherapy drugs (oxaliplatin, fluorouracil, and irinotecan) and also tried cetuximab or bevacizumab, but your cancer continued to grow.
- You are between 18 and 75 years old, in fairly good health (able to do daily activities), and expected to live more than 3 months.
- You must not have had previous treatment with drugs that target both EGFR and c-Met pathways at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called TQB2102 for people with advanced colorectal cancer that has a specific marker called HER2 IHC3+. If you have tried at least two standard treatments and they stopped working or caused side effects, this study may be an option.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests a new drug combination (QL1706 and bevacizumab) for people with advanced colorectal cancer that has a specific genetic feature (MSI-H/dMMR). It aims to see if this treatment can help shrink or control the cancer.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
Hear when a new RAS/BRAF Wild Type Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.